000403 派林生物
已收盘 06-03 15:00:00
资讯
新帖
简况
每周股票复盘：高管连续两日增持派林生物（000403）股份
证券之星 · 05-24
每周股票复盘：高管连续两日增持派林生物（000403）股份
派林生物：5月20日董事司文彬增持股份合计6000股
中金财经 · 05-21
派林生物：5月20日董事司文彬增持股份合计6000股
5月21日派林生物（000403）涨停分析：央企入主、产能放量、研发落地驱动
证券之星 · 05-21
5月21日派林生物（000403）涨停分析：央企入主、产能放量、研发落地驱动
异动快报：派林生物（000403）5月21日14点34分触及涨停板
证券之星 · 05-21
异动快报：派林生物（000403）5月21日14点34分触及涨停板
派林生物：5月19日董事司文彬增持股份合计4000股
证券之星 · 05-20
派林生物：5月19日董事司文彬增持股份合计4000股
派林生物(000403)5月8日股东户数3.87万户，较上期增加0.78%
证券之星 · 05-19
派林生物(000403)5月8日股东户数3.87万户，较上期增加0.78%
派林生物：目前正在履行审批程序
证券之星 · 05-19
派林生物：目前正在履行审批程序
派林生物（000403）披露将参加山西辖区上市公司2026年投资者网上集体接待日活动，5月18日股价下跌3.93%
证券之星 · 05-18
派林生物（000403）披露将参加山西辖区上市公司2026年投资者网上集体接待日活动，5月18日股价下跌3.93%
每周股票复盘：派林生物（000403）2026年一季净利降74.22%
证券之星 · 05-02
每周股票复盘：派林生物（000403）2026年一季净利降74.22%
派林生物（000403）2026年一季报简析：净利润同比下降74.22%，应收账款上升
证券之星 · 04-30
派林生物（000403）2026年一季报简析：净利润同比下降74.22%，应收账款上升
图解派林生物年报：第四季度单季净利润同比下降69.35%
证券之星 · 04-29
图解派林生物年报：第四季度单季净利润同比下降69.35%
股市必读：派林生物（000403）4月17日董秘有最新回复
证券之星 · 04-20
股市必读：派林生物（000403）4月17日董秘有最新回复
派林生物：经核实控股股东股份质押警戒线和平仓线均较低，不存在股份质押风险
证券之星 · 04-17
派林生物：经核实控股股东股份质押警戒线和平仓线均较低，不存在股份质押风险
派林生物最新公告：子公司收到静注人免疫球蛋白及人凝血因子IX药品注册核查通知
证券之星 · 04-13
派林生物最新公告：子公司收到静注人免疫球蛋白及人凝血因子IX药品注册核查通知
派林生物最新公告：全资子公司获得人凝血酶药物临床试验批准通知书
证券之星 · 04-12
派林生物最新公告：全资子公司获得人凝血酶药物临床试验批准通知书
每周股票复盘：派林生物（000403）股东会通过授信担保及战略协议
证券之星 · 03-29
每周股票复盘：派林生物（000403）股东会通过授信担保及战略协议
派林生物：公司2026年3月20日股东人数为39679户
证券之星 · 03-25
派林生物：公司2026年3月20日股东人数为39679户
股市必读：派林生物（000403）3月23日收盘跌5.2%，主力净流出2936.87万元
证券之星 · 03-24
股市必读：派林生物（000403）3月23日收盘跌5.2%，主力净流出2936.87万元
派林生物：公司非常重视海外出口市场布局
证券日报 · 03-23
派林生物：公司非常重视海外出口市场布局
每周股票复盘：派林生物（000403）变更签字注册会计师
证券之星 · 03-22
每周股票复盘：派林生物（000403）变更签字注册会计师
加载更多
公司概况
公司名称：
派斯双林生物制药股份有限公司
所属行业：
医药制造业
上市日期：
1996-06-28
主营业务：
派斯双林生物制药股份有限公司的主营业务是血液制品的研究、开发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ、人凝血酶原复合物。
发行价格：
3.78
{"stockData":{"symbol":"000403","market":"SZ","secType":"STK","nameCN":"派林生物","latestPrice":12.96,"timestamp":1780470225000,"preClose":12.39,"halted":0,"volume":29126758,"delay":0,"changeRate":0.046,"floatShares":941000000,"shares":950000000,"eps":0.3716,"marketStatus":"已收盘","change":0.57,"latestTime":"06-03 15:00:00","open":12.38,"high":12.97,"low":11.89,"amount":361000000,"amplitude":0.0872,"askPrice":12.97,"askSize":948,"bidPrice":12.96,"bidSize":299,"shortable":0,"etf":0,"ttmEps":0.3716,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.39,"symbolType":"stock","openAndCloseTimeList":[[1780450200000,1780457400000],[1780462800000,1780470000000]],"highLimit":13.63,"lowLimit":11.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":950397386,"isCdr":false,"pbRate":1.45,"roa":"--","peRate":34.876211,"roe":"0.28%","epsLYR":0.44,"committee":-0.522699,"marketValue":12317000000,"turnoverRate":0.031,"status":0,"floatMarketCap":12191000000},"requestUrl":"/m/hq/s/000403","defaultTab":"news","newsList":[{"id":"2637734513","title":"每周股票复盘：高管连续两日增持派林生物（000403）股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2637734513","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637734513?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:39","pubTimestamp":1779561550,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，派林生物报收于11.51元，较上周的11.2元上涨2.77%。本周关注点股本股东变化：公司董事、高管司文彬连续两日增持公司股份。股本股东变化高管增减持2026年5月20日，公司董事、高管司文彬增持6000股，占总股本0.0006%，当日收盘价10.5元，期间股价下跌2.96%。截至公告日，同智成科技累计质押42,139,900股，占其所持股份40.33%。北京市嘉源律师事务所出具法律意见书，确认会议合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637331914","title":"派林生物：5月20日董事司文彬增持股份合计6000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637331914","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637331914?lang=zh_cn&edition=full","pubTime":"2026-05-21 21:31","pubTimestamp":1779370305,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月21日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2026年5月20日公司董事,高管司文彬共增持公司股份6000.0股，占公司总股本为0.0006%。变动期间公司股价下跌2.96%，5月20日当日收盘报10.5元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/21/20260521938077.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/21/20260521938077.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260521/32244216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000403","BK0071","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637800038","title":"5月21日派林生物（000403）涨停分析：央企入主、产能放量、研发落地驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2637800038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637800038?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:32","pubTimestamp":1779348748,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物5月21日涨停收盘，收盘价11.55元。该股于13点31分涨停，1次打开涨停，截止收盘封单资金为3889.93万元，占其流通市值0.36%。5月21日的资金流向数据方面，主力资金净流入4205.25万元，占总成交额9.91%，游资资金净流出1039.81万元，占总成交额2.45%，散户资金净流出3165.44万元，占总成交额7.46%。近5日资金流向一览见下表：该股为血制品概念热股，当日血制品概念上涨1.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100023519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637425802","title":"异动快报：派林生物（000403）5月21日14点34分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2637425802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637425802?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:35","pubTimestamp":1779345339,"startTime":"0","endTime":"0","summary":"证券之星5月21日盘中消息，14点34分派林生物（000403）触及涨停板。其所属行业生物制品目前下跌。领涨股为康辰药业。该股为血制品概念热股，当日血制品概念上涨1.37%。5月20日的资金流向数据方面，主力资金净流出2887.59万元，占总成交额23.09%，游资资金净流入1211.03万元，占总成交额9.68%，散户资金净流入1676.55万元，占总成交额13.41%。近5日资金流向一览见下表：派林生物主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100022210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847005","title":"派林生物：5月19日董事司文彬增持股份合计4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847005","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636847005?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:01","pubTimestamp":1779282085,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月20日市场公开信息、上市公司公告及交易所披露数据整理，派林生物最新董监高及相关人员股份变动情况：2026年5月19日公司董事,高管司文彬共增持公司股份4000.0股，占公司总股本为0.0004%。变动期间公司股价上涨0.56%，5月19日当日收盘报10.82元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636834867","title":"派林生物(000403)5月8日股东户数3.87万户，较上期增加0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636834867","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636834867?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:21","pubTimestamp":1779182464,"startTime":"0","endTime":"0","summary":"证券之星消息，近日派林生物披露，截至2026年5月8日公司股东户数为3.87万户，较4月30日增加299.0户，增幅为0.78%。户均持股数量由上期的2.48万股减少至2.46万股，户均持股市值为28.79万元。在生物制品行业个股中，派林生物股东户数高于行业平均水平，截至5月8日，生物制品行业平均股东户数为3.53万户。根据统计，派林生物2026年4月30日至2026年5月8日，主力资金净流出7540.99万元，游资资金净流入3035.79万元，散户资金净流入4505.2万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900030926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636889784","title":"派林生物：目前正在履行审批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2636889784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636889784?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:33","pubTimestamp":1779161634,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问中国生物收购计划是否有变派林生物回复：尊敬的投资者，您好！目前正在履行审批程序，具体请您关注公司《关于控股股东签署＜股份转让协议之补充协议＞暨公司控制权拟发生变更的进展公告》。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900019458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071479","title":"派林生物（000403）披露将参加山西辖区上市公司2026年投资者网上集体接待日活动，5月18日股价下跌3.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071479","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636071479?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:09","pubTimestamp":1779113349,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，派林生物报收于10.76元，较前一交易日下跌3.93%，最新总市值为102.26亿元。近日，派林生物发布《关于参加山西辖区上市公司2026年投资者网上集体接待日活动的公告》。公告显示，公司将于2026年5月22日14:00-17:00通过网络远程方式参加由山西证监局、山西省上市公司协会与深圳市全景网络有限公司联合举办的“山西辖区上市公司2026年投资者网上集体接待日暨年报业绩说明会”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632428426","title":"每周股票复盘：派林生物（000403）2026年一季净利降74.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632428426","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632428426?lang=zh_cn&edition=full","pubTime":"2026-05-02 03:30","pubTimestamp":1777663858,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，派林生物报收于11.95元，较上周的12.55元下跌4.78%。本周关注点股本股东变化：截至2026年3月31日股东户数为3.93万户，较3月20日减少0.84%。业绩披露要点：2026年一季度归母净利润2296.88万元，同比下降74.22%。2026年内将进行中期分红，预计现金分红总额不低于2025年度经审计净利润的30%，具体方案将履行审议程序。2025年公司实现营业收入263,260.73万元，同比下降0.83%；归属于母公司股东的净利润41,926.64万元，同比下降43.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520503","title":"派林生物（000403）2026年一季报简析：净利润同比下降74.22%，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520503","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631520503?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:22","pubTimestamp":1777501321,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期派林生物发布2026年一季报。截至本报告期末，公司营业总收入3.43亿元，同比下降8.47%，归母净利润2296.88万元，同比下降74.22%。本报告期派林生物应收账款上升，应收账款同比增幅达74.04%。然而去年的净利率为15.94%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000020044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631580456","title":"图解派林生物年报：第四季度单季净利润同比下降69.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631580456","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631580456?lang=zh_cn&edition=full","pubTime":"2026-04-29 03:04","pubTimestamp":1777403068,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物2025年年报显示，当年度公司主营收入26.33亿元，同比下降0.83%；归母净利润4.19亿元，同比下降43.75%；扣非净利润3.85亿元，同比下降43.68%；其中2025年第四季度，公司单季度主营收入10.14亿元，同比上升32.71%；单季度归母净利润6208.52万元，同比下降69.35%；单季度扣非净利润6139.02万元，同比下降66.81%；负债率14.63%，投资收益895.35万元，财务费用-3607.68万元，毛利率41.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900007771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628957427","title":"股市必读：派林生物（000403）4月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628957427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628957427?lang=zh_cn&edition=full","pubTime":"2026-04-20 04:41","pubTimestamp":1776631266,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，派林生物报收于12.91元，下跌1.15%，换手率0.69%，成交量6.46万手，成交额8325.91万元。董秘最新回复投资者： 赵总您好！请问公司二级市场股价持续下跌触及平仓线，是否会对收购事项造成影响？经核实控股股东股份质押警戒线和平仓线均较低，不存在股份质押风险。当日关注点来自交易信息汇总：4月17日主力资金净流出512.17万元，占总成交额6.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000001409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0071","000403"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221287","title":"派林生物：经核实控股股东股份质押警戒线和平仓线均较低，不存在股份质押风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221287","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221287?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:36","pubTimestamp":1776396993,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)04月17日在投资者关系平台上答复投资者关心的问题。投资者提问：赵总您好！请问公司二级市场股价持续下跌触及平仓线，是否会对收购事项造成影响？派林生物回复：尊敬的投资者，您好！经核实控股股东股份质押警戒线和平仓线均较低，不存在股份质押风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700020173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627321944","title":"派林生物最新公告：子公司收到静注人免疫球蛋白及人凝血因子IX药品注册核查通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2627321944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627321944?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:00","pubTimestamp":1776078016,"startTime":"0","endTime":"0","summary":"派林生物(000403.SZ)公告称，公司全资子公司广东双林于近日收到国家药监局药审中心下发的关于启动静注人免疫球蛋白及人凝血因子IX药品注册核查的通知。此前，广东双林已分别获得上述两款药品的补充申请受理通知书及注册上市许可受理通知书。目前，这两款药品尚须经国家药监局审批通过后方可上市。公司将按照国家有关规定，积极推进上述研发项目注册核查及审批工作，并根据后续进展情况及时履行信息披露义务。敬请广大投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300026645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626174369","title":"派林生物最新公告：全资子公司获得人凝血酶药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626174369","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626174369?lang=zh_cn&edition=full","pubTime":"2026-04-12 16:10","pubTimestamp":1775981428,"startTime":"0","endTime":"0","summary":"派林生物公告称，公司全资子公司广东双林近日收到国家药监局核准签发的人凝血酶《药物临床试验批准通知书》。目前国内拥有该产品上市批件的企业包括华兰生物及上海莱士。公司表示，此次获得临床试验批准对当期业绩不会产生重大影响，但长期将丰富公司产品线，优化产品结构，提升原料血浆综合利用率和盈利能力，增强核心竞争力。鉴于药品研发具有不确定性，敬请投资者注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200004018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623333505","title":"每周股票复盘：派林生物（000403）股东会通过授信担保及战略协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2623333505","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623333505?lang=zh_cn&edition=full","pubTime":"2026-03-29 04:18","pubTimestamp":1774729091,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，派林生物报收于13.12元，较上周的13.66元下跌3.95%。本周关注点公司公告汇总：2026年第一次临时股东会审议通过子公司授信担保及《战略合作协议之补充协议三》。本次会议审议通过了关于2026年度子公司申请银行授信及为子公司提供担保、签订《战略合作协议之补充协议三》两项议案。北京市嘉源律师事务所对本次会议出具法律意见，认为会议召集、召开程序及表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0071","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622802561","title":"派林生物：公司2026年3月20日股东人数为39679户","url":"https://stock-news.laohu8.com/highlight/detail?id=2622802561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622802561?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:24","pubTimestamp":1774427057,"startTime":"0","endTime":"0","summary":"证券之星消息，派林生物(000403)03月25日在投资者关系平台上答复投资者关心的问题。投资者提问：赵总您好！请问截至2026年3月20日，公司最新的股东人数是多少？派林生物回复：尊敬的投资者，您好！公司2026年3月20日股东人数为39679户。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500030466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621838960","title":"股市必读：派林生物（000403）3月23日收盘跌5.2%，主力净流出2936.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621838960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621838960?lang=zh_cn&edition=full","pubTime":"2026-03-24 01:17","pubTimestamp":1774286269,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，派林生物报收于12.95元，下跌5.2%，换手率1.64%，成交量15.46万手，成交额2.03亿元。交易信息汇总3月23日派林生物收盘报12.95元，跌5.2%，当日成交1546.46万元。该股已连续8日下跌。前10个交易日中，主力资金累计净流出5361.59万元，股价累计下跌8.47%；融资余额累计增加2186.73万元，融券余量累计增加1.53万股。当日资金流向显示，主力资金净流出2936.87万元，游资资金净流入598.9万元，散户资金净流入2337.97万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000403","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621704024","title":"派林生物：公司非常重视海外出口市场布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2621704024","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621704024?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:00","pubTimestamp":1774274400,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月23日，派林生物在互动平台回答投资者提问时表示，公司非常重视海外出口市场布局，一方面积极推进海外产品法规注册及出口销售，另一方面积极探讨推进海外合作项目拓展，以构建海外出口业务长远稳健发展。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-23/doc-inhryxfq2277251.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-23/doc-inhryxfq2277251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0071","000403","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621579945","title":"每周股票复盘：派林生物（000403）变更签字注册会计师","url":"https://stock-news.laohu8.com/highlight/detail?id=2621579945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621579945?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:05","pubTimestamp":1774119914,"startTime":"0","endTime":"0","summary":"公司公告汇总关于变更签字注册会计师的公告派斯双林生物制药股份有限公司于2026年3月18日发布公告，因原签字注册会计师李炳曼女士离职，毕马威华振会计师事务所指派张雪丹女士接替其职务，与王璞共同担任公司2025年度财务报告和内部控制审计的签字注册会计师，质量控制复核人为罗科先生。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0239","000403"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780490777518,"stockEarnings":[{"period":"1week","weight":0.0172},{"period":"1month","weight":0.0368},{"period":"3month","weight":-0.1054},{"period":"6month","weight":-0.1485},{"period":"1year","weight":-0.2607},{"period":"ytd","weight":-0.095}],"compareEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.009},{"period":"3month","weight":-0.0018},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2174},{"period":"ytd","weight":0.0268}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"派斯双林生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38652人(较上一季度增加0.78%)","perCapita":"24337股","listingDate":"1996-06-28","address":"山西省太原市晋源区长兴南街8号阳光城环球金融中心3004室","registeredCapital":"95039万元","survey":" 派斯双林生物制药股份有限公司的主营业务是血液制品的研究、开发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、人免疫球蛋白、乙型肝炎人免疫球蛋白、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、人凝血因子Ⅷ、人凝血酶原复合物。","listedPrice":3.78},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派林生物,000403,派林生物股票,派林生物股票老虎,派林生物股票老虎国际,派林生物行情,派林生物股票行情,派林生物股价,派林生物股市,派林生物股票价格,派林生物股票交易,派林生物股票购买,派林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派林生物(000403)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派林生物(000403)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}